ABBV Research

02Risk & quality

• Consistency 20.0/20 — ABBV has paid for 14 consecutive years — past the 10-year cap on this dimension, so it scores 20/20. Streaks under 25 don't yet qualify as Dividend Aristocrat tier, but represent a meaningful uninterrupted history.
• Payout safety 20.0/20 — ABBV pays out 66.8% of free cash flow as dividends — still inside the safe band, with some headroom before reaching 80%, the level commonly flagged as strained. Manageable as long as earnings hold up.
• Moat 17.6/20 — Scores how protected ABBV's earnings stream is from competition. Operating in Healthcare, ABBV benefits from the kind of brand pricing power, regulatory position, or scale that lets margins hold up through economic cycles. Cyclical or commodity-driven sectors typically score in the single digits here.
• Growth rate 8.4/20 — ABBV's dividend grew about 12.5% per year over 5 years — solid by absolute standards, but a notch below the 15-20% pace seen at growth-oriented dividend payers (think SCHD constituents). Familiar pattern for established staples already paying out most of what they earn — the runway for further hikes naturally narrows once payout ratios climb.
• Balance sheet 10.0/20 — A composite of return-on-equity and inverse leverage. ABBV's ROE leaves this dimension in the middle of the pack — neither flagged for weakness nor in the financial-flexibility tier of top-scoring names.

03Price reference

Below are statistical price references from the last 5 years of trading, anchored to historical drawdown events. They describe where the price has been — not where it should be.